Bio-Rad Laboratories (NYSE:BIO.B) Releases Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings data on Wednesday. The company reported $2.65 earnings per share for the quarter, Zacks reports. The company had revenue of $656.40 million during the quarter. Bio-Rad Laboratories had a return on equity of 3.64% and a net margin of 39.45%.

Bio-Rad Laboratories Stock Performance

NYSE BIO.B remained flat at $379.50 during trading hours on Friday. The company had a trading volume of 1 shares, compared to its average volume of 38. The company has a quick ratio of 2.33, a current ratio of 3.14 and a debt-to-equity ratio of 0.11. The stock has a fifty day simple moving average of $367.22 and a 200-day simple moving average of $312.65. The stock has a market cap of $10.15 billion, a PE ratio of 9.99 and a beta of 0.96. Bio-Rad Laboratories has a 1 year low of $244.54 and a 1 year high of $379.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (NYSE: BIO.B) develops, manufactures and markets products and systems used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers with laboratory instruments, reagents, consumables, software and related services.

Its life science portfolio includes technologies for genomics, digital PCR, protein analysis, chromatography, electrophoresis, cell biology and imaging. Bio-Rad’s clinical diagnostics business provides systems and reagents used in areas such as diabetes monitoring, blood typing, quality control, infectious disease testing and autoimmune diagnostics.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia-Pacific and other international markets.